In The News: SIWA Joins the fight against COVID-19

Home / In The News / In The News: SIWA Joins the fight against COVID-19

SIWA Therapeutics is excited to announce that we are doing our part in the global fight against COVID-19. Our humanized monoclonal antibody targets cells with an abnormally high level of glycolysis (known as the Warburg effect in cancer) and oxidative stress. This category includes, among other things, virally infected cells, including those infected by COVID-19. Read more below:

http://biospace.com/article/chicago-biotech-company-testing-its-monoclonal-antibody-to-treat-covid-19/